Mainstreaming of Genetic Testing Is Tied to Increased Testing Rates in Ovarian Cancer
Ying Liu, MD, MPH, and Tiffany Sia, MD, discuss the benefits of mainstreaming genetic testing in patients with ovarian cancer.
Ying Liu, MD, MPH, and Tiffany Sia, MD, discuss the benefits of mainstreaming genetic testing in patients with ovarian cancer.
Joaquim Bellmunt, MD, PhD, discusses the impact of enfortumab vedotin plus pembrolizumab on the treatment paradigm in first-line urothelial cancer.
Petros Grivas, MD, PhD, discusses the significance of the phase 3 JAVELIN Bladder 100, EV-302, and CheckMate 901 trials in urothelial cancer.
Jonathan E. Rosenberg, MD, discusses ongoing and planned research efforts to enhance the frontline and beyond urothelial cancer treatment landscape.
The phase 3 KeyVibe-010 trial of adjuvant vibostolimab plus pembrolizumab in patients with resected high-risk melanoma has been discontinued.
An abstract is unavailable.
Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.
Asian Americans, Native Hawaiian, and Other Pacific Islanders
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Samilia Obeng-Gyasi, MD, MPH, expands on the impact of social determinants of health on breast cancer care.
Dry, scaly skin can be a sign of many common dermatologic issues, and sometimes even a sign of cancer. We checked with dermatologist Saira George,…